Search

Your search keyword '"Perrotta, Fabio"' showing total 17 results
Start Over Author "Perrotta, Fabio" Publisher the journal of rheumatology
17 results on '"Perrotta, Fabio"'

6. Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study

Author

Macchioni, Pierluigi, primary, Salvarani, Carlo, additional, Possemato, Niccolò, additional, Gutierrez, Marwin, additional, Grassi, Walter, additional, Gasparini, Stefania, additional, Perricone, Carlo, additional, Perrotta, Fabio Massimo, additional, Grembiale, Rosa Daniela, additional, Bruno, Caterina, additional, Tripolino, Cesare, additional, Govoni, Marcello, additional, Ciancio, Giovanni, additional, Farina, Ilaria, additional, Ramonda, Roberta, additional, Frallonardo, Paola, additional, Desiati, Francesca, additional, Scarpa, Raffaele, additional, Costa, Luisa, additional, Zabotti, Alen, additional, De Vita, Salvatore, additional, D’Attino, Rita Maria, additional, Gualberti, Giuliana, additional, Merolla, Rocco, additional, di Luzio Paparatti, Umberto, additional, Aldigeri, Raffaella, additional, and Marchesoni, Antonio, additional

Published
2019
Full Text
View/download PDF

12. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study

Author

Lubrano, Ennio, primary, Massimo Perrotta, Fabio, additional, Manara, Maria, additional, D’Angelo, Salvatore, additional, Addimanda, Olga, additional, Ramonda, Roberta, additional, Punzi, Leonardo, additional, Olivieri, Ignazio, additional, Salvarani, Carlo, additional, and Marchesoni, Antonio, additional

Published
2016
Full Text
View/download PDF

17. Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study

Author

Fabio Massimo Perrotta, Leonardo Punzi, Antonio Marchesoni, Roberta Ramonda, Carlo Salvarani, Salvatore D'Angelo, E. Lubrano, Olga Addimanda, Ignazio Olivieri, Lubrano, Ennio, Perrotta, Fabio Massimo, Marchesoni, Antonio, D'Angelo, Salvatore, Ramonda, Roberta, Addimanda, Olga, Olivieri, Ignazio, Punzi, Leonardo, and Salvarani, Carlo

Subjects
Male, Anti-Inflammatory Agents, Ankylosing spondylitis, Anti-TNF-αdrugs, Nonradiographic axial spondyloarthritis, Remission, Gastroenterology, Receptors, Tumor Necrosis Factor, Etanercept, Retrospective Studie, Immunology and Allergy, Remission Induction, Anti-TNF-αdrug, Antibodies, Monoclonal, Middle Aged, Anti-Inflammatory Agent, Treatment Outcome, Italy, Nonradiographic axial spondyloarthriti, Female, Tumor necrosis factor alpha, Human, medicine.drug, Adult, medicine.medical_specialty, Visual analogue scale, Immunology, Antibodies, Monoclonal, Humanized, ANKYLOSING SPONDYLITIS, ANTI-TNF-α DRUGS, NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, REMISSION, Humans, Immunoglobulin G, Retrospective Studies, Spondylarthritis, Tumor Necrosis Factor-alpha, Rheumatology, Internal medicine, medicine, Adalimumab, Survival analysis, business.industry, Spondylarthriti, Retrospective cohort study, medicine.disease, Infliximab, Ankylosing spondyliti, Physical therapy, business
Abstract

Objective.To investigate the possibility of achieving partial remission (PR) in patients with nonradiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated.Methods.A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was < 20 mm (on a visual analog scale of 0–100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation.Results.A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-α was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%).Conclusion.Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results